Jeri Williams Sells 629 Shares of Axon Enterprise (NASDAQ:AXON) Stock

Axon Enterprise, Inc (NASDAQ:AXON) Director Jeri Williams sold 629 shares of Axon Enterprise stock in a transaction on Monday, June 1st. The shares were sold at an average price of $469.64, for a total value of $295,403.56. Following the sale, the director directly owned 1,141 shares in the company, valued at $535,859.24. The trade was a 35.54% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jeri Williams also recently made the following trade(s):

• On Tuesday, March 17th, Jeri Williams sold 157 shares of Axon Enterprise stock. The shares were sold at an average price of $490.00, for a total value of $76,930.00.

Axon Enterprise Stock Down 1.8%

AXON opened at $481.48 on Thursday. Axon Enterprise, Inc has a one year low of $339.01 and a one year high of $885.91. The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.93 and a current ratio of 2.27. The stock’s fifty day moving average is $406.39 and its 200-day moving average is $492.25. The company has a market capitalization of $38.81 billion, a PE ratio of 193.37, a P/E/G ratio of 8.91 and a beta of 1.45.

Axon Enterprise (NASDAQ:AXON) last posted its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $1.61 EPS for the quarter, topping analysts’ consensus estimates of $1.60 by $0.01. Axon Enterprise had a return on equity of 3.78% and a net margin of 6.90%.The company had revenue of $807.35 million for the quarter, compared to the consensus estimate of $778.91 million. During the same quarter in the previous year, the business earned $1.47 EPS. The company’s quarterly revenue was up 33.7% compared to the same quarter last year. On average, equities analysts predict that Axon Enterprise, Inc will post 1.82 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on the company. Zacks Research raised Axon Enterprise from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, May 19th. Citigroup reissued a “buy” rating on shares of Axon Enterprise in a research note on Wednesday, February 25th. JPMorgan Chase & Co. boosted their price objective on Axon Enterprise from $750.00 to $755.00 and gave the stock an “overweight” rating in a research note on Thursday, May 7th. Piper Sandler dropped their price objective on Axon Enterprise from $690.00 to $674.00 and set an “overweight” rating on the stock in a research note on Thursday, May 7th. Finally, UBS Group dropped their price objective on Axon Enterprise from $570.00 to $440.00 and set a “neutral” rating on the stock in a research note on Thursday, May 7th. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $712.75.

Institutional Investors Weigh In On Axon Enterprise

A number of institutional investors and hedge funds have recently modified their holdings of AXON. Creative Financial Designs Inc. ADV acquired a new stake in shares of Axon Enterprise during the fourth quarter worth $28,000. New Millennium Group LLC acquired a new position in Axon Enterprise during the third quarter valued at $29,000. Sound Income Strategies LLC raised its position in Axon Enterprise by 550.0% during the fourth quarter. Sound Income Strategies LLC now owns 52 shares of the biotechnology company’s stock valued at $30,000 after buying an additional 44 shares during the period. Camelot Portfolios LLC acquired a new position in Axon Enterprise during the fourth quarter valued at $30,000. Finally, AlphaCentric Advisors LLC acquired a new position in Axon Enterprise during the fourth quarter valued at $34,000. 79.08% of the stock is owned by institutional investors and hedge funds.

Axon Enterprise News Summary

Here are the key news stories impacting Axon Enterprise this week:

• Positive Sentiment: Axon’s new Echodyne partnership could deepen its drone and counter-drone capabilities, supporting its push into a high-growth public safety market. Is Axon (AXON) Quietly Building a Defensive Moat With Its New Drone Radar Partnership?
• Positive Sentiment: Axon’s Software & Services segment is showing strong momentum, with recurring revenue and software adoption continuing to expand. Axon’s Software & Services Segment Gains Momentum: Can It Sustain?
• Positive Sentiment: Market commentary continues to frame Axon as part of the “new age defense” and cybersecurity-related trade, which may be helping investor sentiment toward the stock. Palantir, Axon, Crowdstrike, and Cloudflare: New age defense stocks
• Neutral Sentiment: A director sold a relatively small block of shares under a pre-arranged trading plan, which is worth noting but does not necessarily signal a change in fundamentals. Caitlin Elizabeth Kalinowski Sells 564 Shares of Axon Enterprise (NASDAQ:AXON) Stock
• Negative Sentiment: Insider selling by two directors may create some short-term caution, even though the sales were disclosed and appear limited in size relative to Axon’s market value. Caitlin Elizabeth Kalinowski Sells 564 Shares of Axon Enterprise (NASDAQ:AXON) Stock

Axon Enterprise Company Profile

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.